Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.

MedStar author(s):
Citation: Clinical Autonomic Research. 29(1):113-117, 2019 02.PMID: 30229336Institution: MedStar Washington Hospital CenterDepartment: NeurologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antiparkinson Agents/ur [Urine] | *Droxidopa/ur [Urine] | *Hypotension, Orthostatic/dt [Drug Therapy] | *Hypotension, Orthostatic/ur [Urine] | *Kidney/me [Metabolism] | *Norepinephrine/ur [Urine] | Adult | Aged | Antiparkinson Agents/pd [Pharmacology] | Antiparkinson Agents/tu [Therapeutic Use] | Carbidopa/pd [Pharmacology] | Carbidopa/tu [Therapeutic Use] | Carbidopa/ur [Urine] | Droxidopa/pd [Pharmacology] | Droxidopa/tu [Therapeutic Use] | Drug Combinations | Female | Humans | Kidney/de [Drug Effects] | Levodopa/pd [Pharmacology] | Levodopa/tu [Therapeutic Use] | Levodopa/ur [Urine] | Male | Middle AgedYear: 2019ISSN:
  • 0959-9851
Name of journal: Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyAbstract: BACKGROUND: The pressor effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa, NortheraTM) results from conversion of L-DOPS to norepinephrine (NE) in cells expressing L-aromatic-amino-acid decarboxylase (LAAAD). After L-DOPS administration the increase in systemic plasma NE is too small to explain the increase in blood pressure. Renal proximal tubular cells abundantly express LAAAD. Since NE generated locally in the kidneys could contribute to the pressor effect of L-DOPS, in this study we assessed renal conversion of L-DOPS to NE.CONCLUSION: There is extensive renal production of NE from L-DOPS. Carbidopa seems to attenuate the conversion of L-DOPS to NE in the kidneys. Further research is needed to assess whether the proposed paracrine effect of L-DOPS in the kidneys contributes to the systemic pressor response.METHODS: Ten patients who were taking L-DOPS for symptomatic orthostatic hypotension had blood and urine sampled about 2 h after the last L-DOPS dose. L-DOPS and NE were assayed by alumina extraction followed by liquid chromatography with electrochemical detection. Data were compared in patients off vs. on levodopa/carbidopa.RESULTS: In patients off levodopa/carbidopa the ratio of NE/L-DOPS in urine averaged 63 times that in plasma (p = 0.0009 by t test applied to log-transformed data). In marked contrast, in the three patients on levodopa/carbidopa the ratio of NE/L-DOPS in urine did not differ from that in plasma.All authors: Goldstein DS, Holmes C, Lamotte G, Sullivan POriginally published: Clinical Autonomic Research. 2018 Sep 18Fiscal year: FY2019Digital Object Identifier: ORCID: Date added to catalog: 2018-09-28
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30229336 Available 30229336

BACKGROUND: The pressor effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa, NortheraTM) results from conversion of L-DOPS to norepinephrine (NE) in cells expressing L-aromatic-amino-acid decarboxylase (LAAAD). After L-DOPS administration the increase in systemic plasma NE is too small to explain the increase in blood pressure. Renal proximal tubular cells abundantly express LAAAD. Since NE generated locally in the kidneys could contribute to the pressor effect of L-DOPS, in this study we assessed renal conversion of L-DOPS to NE.

CONCLUSION: There is extensive renal production of NE from L-DOPS. Carbidopa seems to attenuate the conversion of L-DOPS to NE in the kidneys. Further research is needed to assess whether the proposed paracrine effect of L-DOPS in the kidneys contributes to the systemic pressor response.

METHODS: Ten patients who were taking L-DOPS for symptomatic orthostatic hypotension had blood and urine sampled about 2 h after the last L-DOPS dose. L-DOPS and NE were assayed by alumina extraction followed by liquid chromatography with electrochemical detection. Data were compared in patients off vs. on levodopa/carbidopa.

RESULTS: In patients off levodopa/carbidopa the ratio of NE/L-DOPS in urine averaged 63 times that in plasma (p = 0.0009 by t test applied to log-transformed data). In marked contrast, in the three patients on levodopa/carbidopa the ratio of NE/L-DOPS in urine did not differ from that in plasma.

English

Powered by Koha